Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype

Holly A. Richendrfer
Mitchell M. Levy
Khaled A. Elsaid
Tannin A. Schmidt
Ling Zhang

See next page for additional authors

Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles

Part of the Amino Acids, Peptides, and Proteins Commons, Animal Experimentation and Research Commons, Cell Biology Commons, Medicinal and Pharmaceutical Chemistry Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, and the Other Pharmacy and Pharmaceutical Sciences Commons
Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype

Comments
This article was originally published in *Critical Care Explorations*, volume 2, issue 6, in 2020. https://doi.org/10.1097/CCE.0000000000000126

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Copyright
The authors

Authors
Holly A. Richendrfer, Mitchell M. Levy, Khaled A. Elsaid, Tannin A. Schmidt, Ling Zhang, Ralph Cabezas, and Gregory D. Jay
Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype

Holly A. Richendrfer, PhD1,2; Mitchell M. Levy, MD3; Khaled A. Elsaid, PharmD, PhD4; Tannin A. Schmidt, PhD3; Ling Zhang, MD1,2; Ralph Cabezas, BS1,2; Gregory D. Jay, MD, PhD1,2

**Objectives:** Sepsis is a leading cause of death in the United States. Putative targets to prevent systemic inflammatory response syndrome include antagonism of toll-like receptors 2 and 4 and CD44 receptors in vascular endothelial cells. Proteoglycan-4 is a mucinous glycoprotein that interacts with CD44 and toll-like receptor 4 resulting in a blockade of the NOD-like receptor pyrin domain-containing-3 pathway. We hypothesized that endothelial cells induced into a sepsis phenotype would have less interleukin-6 expression after recombinant human proteoglycan 4 treatment in vitro.

**Design:** Enzyme-linked immunosorbent assay and reverse transcriptase-quantitative polymerase chain reaction to measure interleukin-6 protein and gene expression.

**Setting:** Research laboratory.

**Subjects:** Human umbilical vascular endothelial cells, human lung microvascular endothelial cells, and transgenic mouse (wild type) (Cd44\(^{+/+}\)/Prg4\(^{+/+}\)), Cd44\(^{−/−}\) (Cd44\(^{+/+}\)Prg4\(^{+/+}\)/Prg4\(^{−/−}\)), Prg4\(^{+/+}\)/Prg4\(^{−/−}\)/Gt4\(^{−/−}\) (Cd44\(^{−/−}\)/Prg4\(^{−/−}\)/Gt4\(^{−/−}\)), and double knockout (Cd44\(^{−/−}\)/Prg4\(^{−/−}\)/Gt4\(^{−/−}\)) lung microvascular endothelial cells.

**Interventions:** Cells were treated with 100 or 250 ng/mL lipopolysaccharide-<i>Escherichia coli</i> K12 and subsequently treated with recombinant human proteoglycan 4 after 30 minutes. Interleukin-6 levels in conditioned media were measured via enzyme-linked immunosorbent assay and gene expression was measured via reverse transcriptase-quantitative polymerase chain reaction with \(ΔΔ\text{Ct}\) analysis. Additionally, human umbilical vascular endothelial cells and human lung microvascular endothelial cells were treated with 1:10 diluted plasma from 15 patients with sepsis in culture media. After 30 minutes, either 50 or 100 µg/mL recombinant human proteoglycan 4 was administered. Interleukin-6 protein and gene expression were assayed. Proteoglycan 4 levels were also compared between control and sepsis patient plasma.

**Measurements and Main Results:** Human umbilical vascular endothelial cell, human lung microvascular endothelial cell, and mouse lung microvascular endothelial cell treated with lipopolysaccharide had significantly increased interleukin-6 protein compared with controls. Recombinant human proteoglycan-4 significantly reduced interleukin-6 in human and mouse endothelial cells. Interleukin-6 gene expression was significantly increased after lipopolysaccharide treatment compared with controls. This response was reversed by 50 or 100 µg/mL recombinant human proteoglycan-4 in 80% of sepsis samples in human umbilical vascular endothelial cells and in 60–73% in human lung microvascular endothelial cells. In Cd44\(^{−/−}\) genotypes of the mouse lung microvascular endothelial cells, recombinant human proteoglycan-4 significantly reduced interleukin-6 protein levels after lipopolysaccharide treatment, indicating that Cd44 is not needed for recombinant human proteoglycan-4 to have an effect in a toll-like receptor 4 agonist inflammation model. Patient sepsis samples had higher plasma levels of native proteoglycan-4 than controls.

**Interpretation and Conclusions:** Recombinant human proteoglycan-4 is a potential adjunct therapy for sepsis patients and warrants future in vivo model studies.

**Key Words:** CD44; cytokines; inflammation; proteoglycan-4; sepsis; toll-like receptors

---

1Department of Emergency Medicine, Warren Alpert School of Medicine, Brown University, Providence, RI.
2Emergency Medicine Research Laboratory, Department of Emergency Medicine, Rhode Island Hospital, Providence, RI.
3Department of Medicine, Division of Pulmonary/Critical Care Medicine, Alpert Medical School at Brown University, Providence, RI.
4Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA.
5Biomedical Engineering Department, University of Connecticut Health Center, Farmington, CT.

Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
**Sepsis** is the body's immune response to infection in major organs including the lung, urinary tract, blood, and skin structures. More than 1.5 million people are diagnosed with sepsis in the United States every year and roughly 250,000 of those patients die due to multiple organ failure with a mortality rate around 33% (1). Antibiotics treat the initiating cause of sepsis but effective treatments intended to blunt immune cell dysfunction are needed.

The body's immune response during sepsis is extensive and includes the up-regulation of pro-inflammatory cytokines, caspases, C-reactive protein, procalcitonin, and transcription factors (2, 3). One of the commonly used biomarkers in sepsis is the cytokine interleukin (IL)-6, which is thought to be indicative of the most severe cases of sepsis and is upregulated in inflammatory cellular pathways (4). IL-6 is a glycoprotein that is released from many different cell types during the immune reaction in response to pathogen-associated molecular patterns or damage-associated molecular patterns (5–8). Because it is noted as a severe sepsis biomarker (4, 8), we chose to focus on the IL-6 response in the current study. At present, there is still no effective treatment that is able to target and counteract the intense immune response during sepsis, making the condition difficult to treat and stabilize (9). Previously the toll-like receptor (TLR)-4 antagonist resatorvid Tak242, a cyclohexene derivative, showed promise in a phase 2 trial (NCT00143611) in patients with acute sepsis but was unable to advance to phase 3 due to iatrogenic methemoglobinemia caused by this small molecule (10).

Lubricin (proteoglycan-4 [PRG4]; genebank number NM_005807) is a mucin-like 224kDa glycoprotein originally found as a lubricating substance within the synovial fluid of diarthrodial joints (11–15). More recently, it has been found in other tissues including lung, liver, brain, heart, bladder, bone, eye, uterus, cervix, and prostate indicating that it serves a multifunctional role (16–18). Lubricin has recently been implicated as an anti-inflammatory mediator in innate immunity pathways (19–21), and CD44 (21–23) has been conceptualized to play a role in its entry into the cytoplasm thereby pointing to its role as a potential adjunct treatment in sepsis. Full-length recombinant human PRG4 (rhPRG4) has been used in limited clinical trials in xerophthalmia and no adverse effects were recorded (24, 25).

Lipopolysaccharide, a potent agonist of the TLRs, was used in this work to recapitulate inflammatory triggers in vitro in endothelial cells that are observed in sepsis (26). We used both lipopolysaccharide and plasma from culture-negative and culture-positive sepsis patients to initiate a strong IL-6 response in human umbilical vascular endothelial cells (HUVECs) and human lung microvascular endothelial cells (HLMVECs). Lipopolysaccharide was also used to treat transgenic mouse lung microvascular endothelial cells (MLMVECs) that were Cd44 sufficient or null. After lipopolysaccharide or patient plasma treatment, cell culture samples were treated with rhPRG4 in order to determine if IL-6 gene expression and protein levels were altered. The results of the current study indicate that rhPRG4 is a potential therapeutic that can be used to reverse the inflammatory response commonly seen in sepsis. Additionally, using transgenic MLMVECs, we show that rhPRG4 reduced IL-6 levels in both the presence and absence of the CD44 receptor and endogenous Prg4, indicating that CD44 may not be required in facilitating anti-inflammatory activity in these cells, especially in regard to TLR4 ligands. Lastly, PRG4 levels in sepsis patient plasma were assayed and compared with controls.

### MATERIALS AND METHODS

**Patient Samples**

Patient plasma samples were obtained from Sepsis, [Extracorporeal Membrane Oxygenation], and [Acute Respiratory Distress Syndrome] biobank patients at Rhode Island Hospital under institutional review board protocol number 4116-16 and used to treat both HUVEC and HLMVEC. Patient demographics are shown in [Supplementary Table 1](http://links.lww.com/CCX/A181).

**Supplementary Materials and Methods** (Supplemental Digital Content 2, http://links.lww.com/CCX/A182) provide additional information.

### RESULTS

**Enzyme-Linked Immunosorbent Assay IL-6 Protein Concentrations**

**HUVEC Culture—Lipopolysaccharide Treatment.** Media from untreated control HUVECs had baseline levels of IL-6 protein of 60.6 ± 1.0 pg/mL. Lipopolysaccharide treatment increased IL-6 protein levels to 671.6 ± 53.39 pg/mL and was significantly higher from media untreated controls (p < 0.001) ([Fig. 1A](#)) IL-6 protein levels were significantly reduced by 5–150 µg/mL rhPRG4 30 minutes after cells were treated with lipopolysaccharide. After lipopolysaccharide treatment, 5 µg/mL rhPRG4 reduced IL-6 levels 32% to 459.9 ± 75.18 pg/mL (p < 0.01), 10 µg/mL rhPRG4 reduced IL-6 levels 48% to 350.0 ± 22.0 pg/mL (p < 0.01), 25 µg/mL rhPRG4 reduced IL-6 levels 88% to 77.7 ± 2.7 pg/mL (p < 0.001), 50 µg/mL rhPRG4 reduced IL-6 levels 91% to 63.84 ± 1.4 pg/mL (p < 0.001), 100 µg/mL rhPRG4 reduced IL-6 levels 94% to 43.1 ± 1.1 pg/mL (p < 0.001), and 150 µg/mL rhPRG4 reduced IL-6 levels 84% to 106.7 ± 15.8 pg/mL (p < 0.001). Cells treated with 25 or 150 µg/mL rhPRG4 alone had IL-6 levels that were not statistically different from untreated controls.

**HLMVEC Culture—Lipopolysaccharide Treatment.** Media from untreated control HLMVECs had baseline levels of IL-6 that were 277.9 ± 23.3 pg/mL. Lipopolysaccharide treatment increased IL-6 levels to 2,733.5 ± 85.4 pg/mL which was significantly higher compared with media untreated controls (p < 0.001) ([Fig. 1B](#)). After 30 minutes of lipopolysaccharide treatment 25, 50, and 100 µg/mL rhPRG4 reduced IL-6 levels 79% to 566.8 ± 26.2, 87% to 349.0 ± 15.7, and 91% to 242.0 ± 10.3 pg/mL (p < 0.001 for all when compared with lipopolysaccharide). Cells treated with 150 µg/mL rhPRG4 alone had IL-6 levels that were not significantly different from untreated controls.

**HUVEC Culture—Patient Plasma Treatment.** Eighty percent of sepsis patient plasma samples lowered IL-6 levels significantly following treatment with 50 µg/mL rhPRG4 (p < 0.05) ([Fig. 2](#)). As a positive control, lipopolysaccharide significantly increased IL-6 levels to 385.7 ± 18.9 pg/mL from 13.6 ± 4.0 pg/mL media levels (p < 0.001) which was reversed with rhPRG4 treatment 97% to 10.3 ± 2.5 pg/mL (p < 0.001) (data not shown). IL-6 values shown in Figure 2 were normalized by subtracting background levels of IL-6 from patient plasma.
HLMVEC Culture—Patient Plasma Treatment. Sixty percent of sepsis patient plasma samples lowered IL-6 levels significantly following treatment with 50 µg/mL rhPRG4 (p < 0.05) (Fig. 3). One sepsis patient plasma sample increased IL-6 levels significantly following treatment with rhPRG4 treatment (p < 0.05, SEA 22). Lipopolysaccharide significantly increased IL-6 protein levels from 96.3 ± 0.8 pg/mL in media controls to 1,318.0 ± 14.4 pg/mL (p < 0.001) which was decreased 81% to 248.9 ± 11.7 pg/mL by 50 µg/mL rhPRG4 (p < 0.001) (data not shown). The IL-6 values shown in Figure 3 were normalized by subtracting background levels of IL-6 from patient plasma.

Lipopolysaccharide significantly increased IL-6 protein levels from 67.1 ± 2.6 pg/mL in media controls to 765.9 ± 12.6 pg/mL.
(\(p < 0.001\)) which was decreased 75% to 193.4 ± 2.2 pg/mL by 100 \(\mu\)g/mL rhPRG4 (\(p < 0.001\)) (data not shown). Seventy-three percent of sepsis patient plasma samples lowered IL-6 levels significantly following treatment with 100 \(\mu\)g/mL rhPRG4 (\(p < 0.05\)) (Fig. 4). Twenty percent of sepsis patient plasma samples increased IL-6 levels significantly following treatment with 100 \(\mu\)g/mL rhPRG4 (SEA 4, SEA 23, and SEA 24). The IL-6 values shown in Figure 4 were normalized by subtracting background levels of IL-6 from patient plasma.

**MLMVEC Culture—Lipopolysaccharide Treatment.** In wild type MLMVECs (Cd44\(^{+/+}\) Prg4\(^{+/+}\)), lipopolysaccharide significantly increased IL-6 protein levels to 307.5 ± 23.7 pg/mL compared with media controls at 12.8 ± 5.3 pg/mL (\(p < 0.001\)) (Fig. 5A). However, all groups co-treated with both lipopolysaccharide and rhPRG4 had significantly reduced IL-6 levels compared with the lipopolysaccharide control group. Compared with the lipopolysaccharide only treated cells, those subsequently treated with 50, 100, and 150 \(\mu\)g/mL rhPRG4 had significantly reduced IL-6 levels that were lowered 26% to 227.3 ± 4.9 pg/mL (\(p < 0.01\)), 69% to 94.4 ± 23.3 pg/mL (\(p < 0.001\)), and 66% to 105.4 ± 10.1 pg/mL (\(p < 0.001\)).

In MLMVECs that were null for Cd44 (Cd44\(^{tm1Hbg}\) Prg4\(^{tm2Mawa/J}\)), lipopolysaccharide treatment significantly increased IL-6 protein levels to 145.1 ± 15.1 pg/mL compared with media controls measured at 2.3 ± 0.8 pg/mL (\(p < 0.001\)) (Fig. 5B). There was no change in IL-6 in cells treated with lipopolysaccharide and then subsequently treated with 50 \(\mu\)g/mL rhPRG4. However, compared with the lipopolysaccharide only group, cells subsequently treated with 100 and 150 \(\mu\)g/mL rhPRG4 had significantly reduced IL-6 levels that were lowered 62% to 55.4 ± 16.1 pg/mL (\(p < 0.001\)) and 58% to 60.9 ± 17.2 pg/mL (\(p < 0.01\)).

In MLMVECs that were double knockout (Cd44\(^{tm1Hbg}\) Prg4\(^{tm2Mawa/J}\)), cells treated with lipopolysaccharide had significantly increased IL-6 levels measured at 167.5 ± 17.1 pg/mL in comparison to media controls at 2.5 ± 0.7 pg/mL (\(p < 0.001\)) (Fig. 5D). Cells treated with lipopolysaccharide and subsequently treated with 50, 100, and 150 \(\mu\)g/mL rhPRG4 had significantly reduced IL-6 compared with lipopolysaccharide only treated cells that were lowered 32% to 113.0 ± 3.1 pg/mL (\(p < 0.01\)), 78% to 36.2 ± 10.7 pg/mL (\(p < 0.001\)), and 80% to 33.5 ± 2.4 pg/mL (\(p < 0.001\)).

**DISCUSSION**

The TLR family includes many members each playing interrelated roles in host defense mechanisms during the immune response (27). Lipopolysaccharide is a strong agonist of the TLRs and upon binding, results in an inflammatory cascade within the cell, leading to the release of cytokines and chemokines, including IL-6 (28, 29). The majority of the culture-positive clinical isolates used...
in this study contained lipopolysaccharide by virtue of the presence of Escherichia coli. The glycoprotein IL-6 is released from many cell types, including endothelial cells (30), as a result of tissue injury or pathogen invasion. It is a ubiquitous biomarker of severe sepsis in both neonates and adults (4, 6–8, 31–35). Therefore, we chose to evaluate IL-6 protein and gene expression in the current study as a representation of a sepsis-like response by mouse and human endothelial cells. Endothelial cells were chosen because their function is highly affected during sepsis (36). Barrier function, signal transduction, vasoregulation, and blood coagulation are all affected by endothelial cells due to their intimal location in blood vessels (36). Dyscrasias in endothelial cells caused by sepsis play a major role in blood vessel permeability, acidosis, and coagulopathy. Macrophages were not studied in this investigation as we have already shown that NOD-like receptor pyrin domain-containing-3 (NLRP3) is inhibited by rhPRG4 in a human leukemia monocytic cell line THP-1 cells (21).

The lipopolysaccharide used in the current study was the E. coli K12-ultrapure variety which only activates TLR4 receptors. Levels of IL-6 protein and gene expression significantly increased in HUVECs, HLMVECs, and MLMVECs after cells were treated with lipopolysaccharide in the current study. Furthermore, the results of the current study show that even though lipopolysaccharide elicited a significant increase of IL-6 protein levels and gene expression in HUVECs, HLMVECs, and MLMVECs these levels were reversed by rhPRG4 in a concentration-dependent manner. Although this study is the first of its kind to use endothelial cells treated with rhPRG4, the results indicate that rhPRG4 has strong anti-inflammatory properties consistent with similar studies in other cell types, pointing to an anti-inflammatory role of lubricin (19–23). These studies indicate that PRG4 has two biological mechanisms of action within the cell in order to counteract inflammation.

Both native human PRG4 (nhPRG4) and rhPRG4 were found to bind to and act as an antagonist to TLR2 and TLR4 receptors in the human embryonic kidney-293 reporter cell line which was verified using enzyme-linked immunosorbent assay, flow cytometry, and immunoprecipitation (19). nhPRG4 was also able to block activation of both TLR2 and TLR4 after the agonists synthetic triacylated lipoprotein and lipopolysaccharide were used, further supporting the role of PRG4 as an anti-inflammatory biologic (19). These results fall in line with the results of our current study in that rhPRG4 competes with lipopolysaccharide in a concentration-dependent manner in order to prevent and reverse inflammation because the addition of rhPRG4 in our experiments occurred “after” cells were exposed to lipopolysaccharide. In using MLMVECs that were null for Cd44, there remained a reduction in IL-6 following rhPRG4 treatment, indicating that its anti-inflammatory properties are not dependent on an interaction with CD44. Overall, endothelial cells that were Cd44 null (Cd44<sup>-/-</sup>;Prg4<sup>+/+</sup>) and Cd44<sup>+/−</sup>;Prg4<sup>+/+</sup>) showed a net lower level of IL-6 upon exposure to lipopolysaccharide indicating that animals sufficient for lipopolysaccharide were used, further supporting the role of PRG4 as an anti-inflammatory biologic (19). These results fall in line with the results of our current study. Furthermore, the results of the current study show that even though lipopolysaccharide elicited a significant increase of IL-6 protein levels and gene expression in HUVECs, HLMVECs, and MLMVECs these levels were reversed by rhPRG4 in a concentration-dependent manner. Although this study is the first of its kind to use endothelial cells treated with rhPRG4, the results indicate that rhPRG4 has strong anti-inflammatory properties consistent with similar studies in other cell types, pointing to an anti-inflammatory role of lubricin (19–23). These studies indicate that PRG4 has two biological mechanisms of action within the cell in order to counteract inflammation.

Both native human PRG4 (nhPRG4) and rhPRG4 were found to bind to and act as an antagonist to TLR2 and TLR4 receptors in the human embryonic kidney-293 reporter cell line which was verified using enzyme-linked immunosorbent assay, flow cytometry, and immunoprecipitation (19). nhPRG4 was also able to block activation of both TLR2 and TLR4 after the agonists synthetic triacylated lipoprotein and lipopolysaccharide were used, further supporting the role of PRG4 as an anti-inflammatory biologic (19). These results fall in line with the results of our current study in that rhPRG4 competes with lipopolysaccharide in a concentration-dependent manner in order to prevent and reverse inflammation because the addition of rhPRG4 in our experiments occurred “after” cells were exposed to lipopolysaccharide. In using MLMVECs that were null for Cd44, there remained a reduction in IL-6 following rhPRG4 treatment, indicating that its anti-inflammatory properties are not dependent on an interaction with CD44. Overall, endothelial cells that were Cd44 null (Cd44<sup>-/-</sup>;Prg4<sup>+/+</sup>) and Cd44<sup>+/−</sup>;Prg4<sup>+/+</sup>) showed a net lower level of IL-6 upon exposure to lipopolysaccharide indicating that animals sufficient for Cd44 may have greater inflammatory effects from an induced cellular sepsis response. We also observed in Figure 5 that rhPRG4 is more effective than the endothelial cell's native Prg4 in lowering IL-6.

Inflammatory cascades within many cell types, including endothelial cells, are also activated via activation of the CD44 receptor. If the inflammatory cascades are activated within the cell, the NLRP3 inflammasome becomes activated and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) nuclear translocation occurs, both of which drive cytokine release from the cell (21, 22, 37–40). Previous studies indicate that rhPRG4 blocks NF-κB translocation and prevents activation of the NLRP3 inflammasome after it is
internalized in the cell (22). The results from that study indicated that aside from the well-known agonist, hyaluronic acid, rhPRG4 is also a ligand for the CD44 receptor and binds with a higher affinity than HA (22). However, rhPRG4 still showed anti-inflammatory properties in endothelial cells null for Cd44. Therefore, it is possible that rhPRG4 exerted its effects via a different mechanism, such as inactivation of TLR4 and possible cellular internalization via other receptor-mediated and nonreceptor mediated pathways.

Based upon the results of the current study and previous studies, it appears that rhPRG4 may be useful as an adjunct therapeutic for a variety of disorders with an immune reaction, including sepsis by either antagonizing TLR2 and TLR4, as was recently reviewed (41). Although a CD44 dependent mechanism in endothelial cells was not observed, this cell surface receptor may still be involved in other immune cells such as macrophages (21). TLR2 and TLR4 have been antagonized in the past in clinical studies using small molecules (10) which appeared promising but eluded translation. PRG4 is normally present in the serum in low levels as it is expressed by hepatocytes and many other organ systems (16–18, 42). In our study, sepsis patients showed higher overall PRG4 levels in plasma in comparison to control patients which indicate that PRG4 may act as an antagonist in the sepsis response in humans (Supplementary Results, Supplemental Digital Content 8, http://links.lww.com/CCX/A188). However, there was no within-subject correlation between IL-6 and PRG4 levels in sepsis patient plasma which could be due to the timing of plasma collection and sepsis severity. In a mouse sepsis model, an organ-based proteomics study (43) indicated that both protein and transcript levels of Prg4 were upregulated in the liver suggesting it may act as an antagonist of the sepsis response in a murine model as well.

When endothelial cells were treated with plasma from septic patients, the results of IL-6 protein levels and gene expression (Supplementary Results, Supplemental Digital Content 8, http://links.lww.com/CCX/A188) did not share the same magnitude of change as the results from cells treated with only lipopolysaccharide. This may have been due to our RNA collection timepoint at 24 hours post lipopolysaccharide and rhPRG4 treatment or due to the array of inflammatory factors in the septic plasma. Plasma from septic patients can contain either gram-positive and negative bacterial components and a variety of cytokines. These components can further amplify inflammation as measured in our assays via interaction with tumor necrosis factor receptor, CD44, and other targets which may explain why rhPRG4 did not decrease IL-6 protein and gene expression in all cell samples treated with septic patient plasma (44–49). Furthermore, it is also possible that gene expression analysis should have been performed at an earlier timepoint than 24 hours post-treatment with patient plasma due to the latency between upregulated gene expression and subsequent protein release. For example, it has been reported that peak cytokine release occurs between 2 and 6 hours post lipopolysaccharide administration in macrophages and liver tissue (50–52). Unfortunately, due to limitations on patient plasma availability, only one timepoint was used for both protein and RNA analysis in our study.

As far as limitations of our study, we believe this study is relevant to the early stages of sepsis that are lipopolysaccharide dependent. Sepsis is a complicated disease process that takes time to evolve; as it does, a biomolecule like PRG4 theoretically becomes less effective. Ongoing work on additional patient samples will be conducted in order to study endothelial cell gene expression at earlier sepsis timepoints post lipopolysaccharide and rhPRG4 treatment in vitro. We are presently also using an in vivo mouse model to test the effects of rhPRG4 in an lipopolysaccharide-induced sepsis model.

CONCLUSIONS

Based upon the data presented in the current study, innate immune cellular responses of IL-6 from HUVECs, HLMVECs, and MLMVECs can be reversed by treatment with rhPRG4. Therefore, we believe that rhPRG4 is deserving of additional study as a potential adjunct therapeutic for sepsis patients.

ACKNOWLEDGMENTS

We thank Virginia Hovanesian (Rhode Island Hospital) for her expertise with fluorescence imaging of samples. We also thank Thomas Walsh (Rhode Island Hospital) for his help with gathering patient plasma samples. We also thank Janette Baird, PhD (Brown University) for her statistical advice.

Supplemental digital content is available for this article. Direct URL citations appear in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/cc ejournal).

Drs. Schmidt and Jay have authored patents relating to and financial interest in recombinant human proteoglycan-4 production (Lubris, LLC). Drs. Elsaïd and Jay have received funding from National Institutes of Health grant R01AR067748. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: Gregory_jay_md@brown.edu

This work was performed in the Department of Emergency Medicine, Rhode Island Hospital/Brown University.

REFERENCES

1. Centers for Disease Control and Prevention: Sepsis 2020. Available at: https://www.cdc.gov/sepsis/datareports/index.html. Accessed January 1, 2020
2. Aziz M, Jacob A, Wang P: Revisiting caspases in sepsis. Cell Death Dis 2014; 5:e1526
3. de Oliveira VM, Moraes RB, Stein AT, et al: Accuracy of C - reactive protein as a bacterial infection marker in critically immunosuppressed patients: A systematic review and meta-analysis. J Crit Care 2017; 42:129–137
4. Franco DM, Arealvo-Rodriguez I, i Figuls MR, et al: Interleukin-6 for diagnosis of sepsis in critically ill adult patients. Cochrane Database Syst Rev 2015; 2015:CD011811
5. Kobeissi Z, Zanotti-Cavazzoni S: Biomarkers of sepsis Marshall JC, for the Septic Shock (Sepsis) Island Hospital/Brown University.

www.ccejournal.org
10. Rice TW, Wheeler AP, Bernard GR, et al: A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38:1685–1694
11. Jay GD, Britt DE, Cha CJ: Lubricin is a product of megakaryocyte stimulating factor gene expression by human synovial fibroblasts. J Rheumatol 2000; 27:594–600
12. Swann DA, Hendren RB, Radin EL, et al: The lubricating activity of synovial fluid glycoproteins. Arthritis Rheum 1981; 24:22–30
13. Swann DA, Silver FH, Slayter HS, et al: The molecular structure and lubricating activity of lubricin isolated from bovine and human synovial fluids. Biochem J 1985; 225:195–201
14. Swann DA, Slayter HS, Silver FH: The molecular structure of lubricating glycoprotein-I, the boundary lubricant for articular cartilage. J Biol Chem 1981; 256:5921–5925
15. Swann DA, Sotman S, Dixon M, et al: The isolation and partial characterization of the major glycoprotein (LGP-1) from the articular lubricating fraction from bovine synovial fluid. Biochem J 1977; 161:473–485
16. Ikegawa S, Sano M, Koshizuka Y, et al: Isolation, characterization and mapping of the mouse and human PRG4 (proteoglycan 4) genes. Cytogeten Cell Genet 2000; 90:291–297
17. Schmidt TA, Sullivan DA, Knop E, et al: Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol 2013; 131:766–776
18. Flannery CR, Hughes CE, Schumacher BL, et al: Articular cartilage superficial zone protein (SZP) is homologous to megakaryocyte stimulating factor precursor and is a multifunctional proteoglycan with potential growth-promoting, cytoprotective, and lubricating properties in cartilage metabolism. Biochem Biophys Res Commun 1999; 254:535–541
19. Alquraini A, Gargulo S, D’Souza G, et al: The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: An anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther 2015; 17:353
20. Iqbal SM, Leonard C, Regmi SC, et al: Lubricin/proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep 2016; 6:18910
21. Qadri M, Jay GD, Zhang LX, et al: Recombinant human proteoglycan-4 reduces phosphogycrosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of cytokines and chemokines in human and murine macrophages. Arthritis Res Ther 2018; 20:192
22. Al-Sharif A, Jamal M, Zhang LX, et al: Lubricin/proteoglycan 4 binding to CD44 receptor: A mechanism of the suppression of proinflammatory cytokine-induced synoviocyte proliferation by lubricin. Arthritis Rheumatol 2015; 67:1503–1513
23. Sarkar A, Chanda A, Regmi SC, et al: Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFβ-Hyaluronan-CD44 signalling pathway. PLoS One 2019; 14:e0219697
24. Lambiase A, Sullivan BD, Schmidt TA, et al: A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 μg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease. Ocul Surf 2017; 15:77–87
25. U.S. National Library of Medicine: Tolerability, Safety and Efficacy of lubricin 150 μg/mL eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease. www.ccejournal.org
26. Song WC: Crosstalk between complement and toll-like receptors. Toxicol Pathol 2012; 40:174–182
27. Chen K, Huang J, Gong W, et al: Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007; 7:1217–1285
28. Zeuke S, Ulmer AJ, Kusumoto S, et al: TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56:126–134
29. Krikun G, Trezza J, Shaw J, et al: Lipopolysaccharide appears to activate human endometrial endothelial cells through TLR4-dependent and TLR4-independent mechanisms. Am J Reprod Immunol 2012; 68:233–237
30. Podor TJ, Jirik FR, Loskutoff DJ, et al: Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci 1989; 557:374–385; discussion 386–387
31. Andaluz-Ojeda D, Bobillo F, Iglesias V, et al: A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. Cytokine 2012; 57:332–336
32. Biron BM, Ayala A, Lomas-Neira JL: Biomarkers for sepsis: What is and what might be? Biomark Insights 2015; 10:7–17
33. Gogos CA, Drosou E, Bassaris HP, et al: Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176–180
34. Rios-Toro J, Márquez-Coello M, García-Álvarez JM, et al: Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock. PLoS One 2017; 12:e0175254
35. Sun B, Liang LF, Li J, et al: A meta-analysis of interleukin-6 as a valid and accurate index in diagnosing early neonatal sepsis. Int Wound J 2019; 16:527–533
36. Ince C, Mayeux PR, Nguyen T, et al: ADQI XIV Workgroup: The endothelium in sepsis. Shock 2016; 45:259–270
37. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1:a001651
38. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2:725–734
39. Afonina IS, Zhong Z, Karin M, et al: Limiting inflammation-the negative regulation of NF-kB and the NLRP3 inflammasome. Nat Immunol 2017; 18:861–869
40. He Y, Hara H, Núñez G: Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 2016; 41:1012–1021
41. Richendrfer H, Jay GD: Lubricin as a therapeutic and potential biomarker in sepsis. Crit Care Clin 2020; 36:55–67
42. Al M, Cai Y, Sy MS, et al: Anti-lubricin monoclonal antibodies created using lubricin-knockout mice immunodetect lubricin in several species and in patients with healthy and diseased joints. PLoS One 2015; 10:e0116237
43. Toledo AG, Golden G, Campos AR, et al: Proteomic atlas of organ vasculopathies triggered by Staphylococcus aureus sepsis. Nat Commun 2019; 10:4656
44. Meyer NJ, Reilly JP, Anderson BJ, et al: Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med 2018; 46:21–28
45. Wang Y, Liu Q, Liu T, et al: Early plasma monocyte chemoattractant protein-1 predicts the development of sepsis in trauma patients: A prospective observational study. Medicine 2018; 97:e0356
46. Wu X, Yang J, Yu L, et al: Plasma miRNA-223 correlates with risk, inflammatory markers as well as prognosis in sepsis patients. Medicine 2018; 97:e11352-e
47. Klaus DA, Seemann R, Roth-Walter F, et al: Plasma levels of chemokine ligand 20 and chemokine receptor 6 in patients with sepsis: A case control study. Eur J Anaesthesiol 2016; 33:348–355
48. Lin WC, Chen CW, Chao L, et al: Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One 2017; 12:e0178387
49. Boyd JH, Fjell CD, Russell JA, et al: Increased plasma monocyte chemoattractant protein-1 receptor antagonist plasma concentration. Crit Care Med 2018; 46:21–28
50. Tanaka A, To J, O’Brien B, et al: Selection of reliable reference genes for the normalisation of gene expression levels following time course LPS stimulation of murine bone marrow derived macrophages. BMC Immunol 2017; 18:43
51. Schroder K, Irvine KM, Taylor MS, et al: Conservation and divergence in toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci U S A 2012; 109:E944–E953
52. Everhardt Queen A, Moedryk-Schauwecker M, McKee LM, et al: Differential expression of inflammatory cytokines and stress genes in male and female mice in response to a lipopolysaccharide challenge. PLoS One 2016; 11:e0152289